Sugi Predict

Sugi Predict / Compounds / Ribose (Furanose)

Ribose (Furanose)

Ribose (Furanose)

SCHEMBL5526657

O=c1cc[nH]c(=O)[nH]1.OC[C@H]1O[C@@H](O)[C@@H](O)[C@@H]1O

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ CRBN Q96SW2 1/20 0.52
▸ SLC28A1 O00337 1/20 0.48
▸ SLC28A2 O43868 1/20 0.48
▸ SLC29A1 Q99808 1/20 0.48
▸ SLC28A3 Q9HAS3 1/20 0.48
▸ ALDH1A1 P00352 1/20 0.46
▸ P2RY14 Q15391 4/20 0.37
▸ P2RY2 P41231 2/20 0.37
▸ P2RY4 P51582 1/20 0.37
▸ PYGM P11217 3/20 0.36
▸ ATM Q13315 1/20 0.36
▸ HK1 P19367 1/20 0.36
▸ HK2 P52789 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ribose (Furanose) SCHEMBL2751838 1.00 CRBN (0.52) CRBNSLC28A1SLC28A2SLC29A1SLC28A3
Ribose (Furanose) SCHEMBL16337481 1.00 CRBN (0.52) CRBNSLC28A1SLC28A2SLC29A1SLC28A3
Ribose (Furanose) SCHEMBL4632749 1.00 CRBN (0.52) CRBNSLC28A1SLC28A2SLC29A1SLC28A3
Ribose (Furanose) SCHEMBL8133174 0.85 TP53 (0.54) SLC28A1SLC28A2SLC29A1SLC28A3ALDH1A1
Uracil SCHEMBL11132447 0.82 P2RY14 (0.51) P2RY14P2RY2P2RY4
Uracil SCHEMBL15575574 0.81 CRBN (0.41) CRBNSLC28A1SLC28A2SLC29A1SLC28A3
Uridine SCHEMBL28497231 0.80 SLC28A1 (0.81) SLC28A1SLC28A2SLC29A1SLC28A3P2RY14
Uridine SCHEMBL10458586 0.80 SLC28A1 (0.81) SLC28A1SLC28A2SLC29A1SLC28A3P2RY14
Uridine SCHEMBL440742 0.80 SLC28A1 (0.81) SLC28A1SLC28A2SLC29A1SLC28A3P2RY14
Uracil SCHEMBL4193859 0.78 CRBN (0.47) CRBNSLC28A1SLC28A2SLC29A1SLC28A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5352584-A Radioimmunoassay or enzyme-linked immunosorbent assay for qunatitative analysis E. R. SQUIBB & SONS, INC. (US) 1994-10-04 — — US claimed
US-4022963-A Acetylation process for nucleoside compounds DEUTSCH DANIEL HAROLD 1977-05-10 — — US claimed
US-20230365632-A1 A GROUP OF PEPTIDE DERIVATIVE OMICSYNINS WITH ANTIVIRAL ACTIVITY AND USES THEREOF INSTITUTE OF MEDICINAL BIOTECHNOLOGY CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2023-11-16 — — US disclosed
EP-4123031-A1 METHODS FOR DETECTING AGGLUTINATION AND COMPOSITIONS FOR USE IN PRACTICING THE SAME The Regents of The University of California (US) 2023-01-25 — — EP disclosed
EP-3283638-B1 METHODS FOR DETECTING AGGLUTINATION AND USE OF KITS IN PRACTICING THE SAME UNIV CALIFORNIA (US) 2022-06-08 — — EP disclosed
US-20210403978-A1 METHODS FOR DETECTING AGGLUTINATION AND COMPOSITIONS FOR USE IN PRACTICING THE SAME THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2021-12-30 — — US disclosed
US-11149296-B2 Methods for detecting agglutination and compositions for use in practicing the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-10-19 — — US disclosed
US-20200232005-A1 Methods of Producing and Using Single-Stranded Deoxyribonucleic Acids and Compositions for Use in Practicing the Same TAKARA BIO USA, INC. 2020-07-23 — — US disclosed
US-10584363-B2 Methods of producing and using single-stranded deoxyribonucleic acids and compositions for use in practicing the same TAKARA BIO USA, INC. (US) 2020-03-10 — — US disclosed
US-20180100181-A1 METHODS FOR DETECTING AGGLUTINATION AND COMPOSITIONS FOR USE IN PRACTICING THE SAME THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2018-04-12 — — US disclosed
US-20170349927-A1 METHODS OF PRODUCING AND USING SINGLE-STRANDED DEOXYRIBONUCLEIC ACIDS AND COMPOSITIONS FOR USE IN PRACTICING THE SAME TAKARA BIO USA, INC. 2017-12-07 — — US disclosed
EP-0355135-B1 ADENOSINE DEAMINASE-STABLE ANTI-RETROVIRAL NUCLEOSIDES SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) 1993-08-04 — — EP disclosed
EP-0475160-A1 Preparation for drug application in minute droplet form Cevc, Gregor, Prof. Dr. (DE) 1992-03-18 — — EP disclosed
WO-1992003122-A1 PREPARATION FOR APPLICATION OF ACTIVE SUBSTANCES IN THE FORM OF MINIMUM-SIZED DROPLETS CEVC GREGOR (DE) 1992-03-05 — — WO disclosed
EP-0439117-A1 Monoclonal antibodies which bind (E)-5-(2-bromovinyl)-arabinofuranosyluracil and diagnostic methods based thereon E.R. SQUIBB & SONS, INC. (US) 1991-07-31 — — EP disclosed
US-4997926-A Viricides SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) 1991-03-05 — — US disclosed
EP-0355135-A4 ADENOSINE DEAMINASE-STABLE ANTI-RETROVIRAL NUCLEOSIDES. SCRIPPS CLINIC RES (US) 1990-04-09 — — EP disclosed
EP-0355135-A1 ADENOSINE DEAMINASE-STABLE ANTI-RETROVIRAL NUCLEOSIDES SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) 1990-02-28 — — EP disclosed
WO-1989004662-A1 ADENOSINE DEAMINASE-STABLE ANTI-RETROVIRAL NUCLEOSIDES SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) 1989-06-01 — — WO disclosed
US-4022963-A Acetylation process for nucleoside compounds DEUTSCH DANIEL HAROLD 1977-05-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365632-A1 A GROUP OF PEPTIDE DERIVATIVE OMICSYNINS WITH ANTIVIRAL ACTIVITY AND USES THEREOF CCL5, CYTH3, HRH3 CRBN 175/4885SLC28A1 4423/4885SLC28A2 4462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.